UBS Group
ANIP icon

UBS Group’s ANI Pharmaceuticals ANIP Stock Holding History

UBS Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.6M Sell
297,539
-200,163
-40% -$16.1M ﹤0.01% 2462
2026
Q1 		$38.3M Buy
497,702
+346,923
+230% +$27.1M 0.01% 1909
2025
Q4 		$11.9M Sell
150,779
-439,095
-74% -$38M ﹤0.01% 3113
2025
Q3 		$54M Buy
589,874
+185,172
+46% +$15.1M 0.01% 1548
2025
Q2 		$26.4M Buy
404,702
+140,312
+53% +$9.14M ﹤0.01% 2090
2025
Q1 		$17.7M Sell
264,390
-330,420
-56% -$19.7M ﹤0.01% 2461
2024
Q4 		$32.9M Buy
594,810
+308,322
+108% +$17.7M 0.01% 1836
2024
Q3 		$17.1M Buy
286,488
+254,514
+796% +$15.5M ﹤0.01% 1957
2024
Q2 		$2.04M Buy
31,974
+14,512
+83% +$942K ﹤0.01% 3756
2024
Q1 		$1.21M Sell
17,462
-1,569
-8% -$94.7K ﹤0.01% 4452
2023
Q4 		$1.05M Buy
19,031
+12,853
+208% +$708K ﹤0.01% 4455
2023
Q3 		$359K Sell
6,178
-25,895
-81% -$1.49M ﹤0.01% 4913
2023
Q2 		$1.73M Buy
32,073
+20,376
+174% +$903K ﹤0.01% 3674
2023
Q1 		$465K Buy
11,697
+4,880
+72% +$206K ﹤0.01% 4748
2022
Q4 		$274K Buy
6,817
+6,773
+15,393% +$254K ﹤0.01% 5208
2022
Q3 		$1K Buy
+44
New +$1.51K ﹤0.01% 9917
2022
Q2 		– Sell
-481
Closed -$14K – 10268
2022
Q1 		$14K Sell
481
-5,420
-92% -$202K ﹤0.01% 7919
2021
Q4 		$273K Buy
5,901
+4,274
+263% +$184K ﹤0.01% 5432
2021
Q3 		$53K Sell
1,627
-733
-31% -$22.8K ﹤0.01% 6285
2021
Q2 		$83K Sell
2,360
-1,603
-40% -$54.5K ﹤0.01% 6022
2021
Q1 		$144K Sell
3,963
-1,030
-21% -$32.2K ﹤0.01% 5686
2020
Q4 		$145K Sell
4,993
-2,988
-37% -$85.6K ﹤0.01% 5451
2020
Q3 		$226K Sell
7,981
-10,009
-56% -$298K ﹤0.01% 4722
2020
Q2 		$581K Buy
17,990
+10,373
+136% +$372K ﹤0.01% 4009
2020
Q1 		$311K Sell
7,617
-7,578
-50% -$403K ﹤0.01% 4365
2019
Q4 		$937K Buy
15,195
+5,521
+57% +$366K ﹤0.01% 4280
2019
Q3 		$706K Buy
9,674
+5,384
+126% +$403K ﹤0.01% 4264
2019
Q2 		$353K Buy
4,290
+4,170
+3,475% +$297K ﹤0.01% 4534
2019
Q1 		$8K Sell
120
-98
-45% -$5.77K ﹤0.01% 6922
2018
Q4 		$10K Sell
218
-1,536
-88% -$80.5K ﹤0.01% 7223
2018
Q3 		$99K Buy
1,754
+1,085
+162% +$66.4K ﹤0.01% 5608
2018
Q2 		$45K Sell
669
-835
-56% -$52.1K ﹤0.01% 6055
2018
Q1 		$88K Buy
1,504
+1,208
+408% +$76.7K ﹤0.01% 5300
2017
Q4 		$19K Sell
296
-2,496
-89% -$155K ﹤0.01% 6585
2017
Q3 		$147K Buy
2,792
+558
+25% +$26.6K ﹤0.01% 5059
2017
Q2 		$105K Sell
2,234
-2,378
-52% -$115K ﹤0.01% 5139
2017
Q1 		$228K Sell
4,612
-2,287
-33% -$128K ﹤0.01% 4575
2016
Q4 		$418K Sell
6,899
-12,388
-64% -$757K ﹤0.01% 4256
2016
Q3 		$1.28M Buy
19,287
+4,748
+33% +$297K ﹤0.01% 3239
2016
Q2 		$812K Buy
14,539
+12,613
+655% +$613K ﹤0.01% 3552
2016
Q1 		$65K Sell
1,926
-29
-1% -$984 ﹤0.01% 5292
2015
Q4 		$88K Buy
1,955
+1,896
+3,214% +$81.6K ﹤0.01% 5314
2015
Q3 		$2K Sell
59
-8,590
-99% -$489K ﹤0.01% 8053
2015
Q2 		$537K Buy
8,649
+5,930
+218% +$353K ﹤0.01% 4063
2015
Q1 		$170K Buy
2,719
+1,969
+263% +$120K ﹤0.01% 5000
2014
Q4 		$42K Buy
+750
New +$33.1K ﹤0.01% 6691

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's ANIP Position: Q2 2026 in Review

UBS Group reduced its ANI Pharmaceuticals (ANIP) stake by 40% in Q2 2026, selling an estimated $16.1M and leaving 297,539 shares worth $24.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2462.

UBS Group first reported a position in ANIP in Q4 2014 and has held it in 46 quarters since. The position peaked at $54M in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • UBS Group held 297,539 shares of ANI Pharmaceuticals worth $24.6M as of Q2 2026.
  • UBS Group sold 200,163 ANI Pharmaceuticals shares in Q2 2026, an estimated $16.1M.
  • ANI Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2462 holding.
  • UBS Group first reported a position in ANI Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's ANI Pharmaceuticals position peaked at $54M in Q3 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.